Svennilson Peter
Follow13F filer, CIK 1606074, SAN FRANCISCO, CA
Svennilson Peter reported $837,452,000 across 5 holdings for the quarter ended 2019-12-31, in a 13F-HR filed 2020-02-12.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-20-001647
- Period
- 2019-12-31
- Reported value
- $837M
- Holdings
- 5
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 0
Stakes and trades reported after 2019-12-31
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
Accepted , ingested - TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| RAPT THERAPEUTICS INCnew | +6,777,151 | $187M |
| NGM BIOPHARMACEUTICALS INCadded | +253,922 | $4.7M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
None.
Holdings, Q4 2019
Share positions as resolved from 13F-HR 0000950123-20-001647, largest first. % of portfolio is the value over $837,452,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 16,420,829 | $304M | 36.26% | +253,922 | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 6,009,702 | $283M | 33.81% | 0 | |||
| RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC | 6,777,151 | $187M | 22.34% | new | |||
| RCUSARCUS BIOSCIENCES INC | 3,540,850 | $35.8M | 4.27% | 0 | Timeline | ||
| GRITSTONE BIO INCGRITSTONE BIO INC | 3,102,934 | $27.8M | 3.32% | 0 |
How Q4 2019 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-20-001647 | base | 2020-02-12 | acceptance time not in the bulk data set |